This presentation provides an in-depth overview of the Accelerating Medicines Partnership® Schizophrenia (AMP SCZ) initiative, a collaborative effort aimed at enhancing our understanding of the critical period before the first onset of psychosis in those who go on to develop schizophrenia. Participants will explore the initiative's primary goals, including the development of tools to improve the success of pharmacologic treatments for individuals at clinical high risk (CHR) for psychosis. The session will highlight the integration of lived experience into research and governance structures, demonstrating how this approach enriches scientific endeavors and ethical practices. Additionally, attendees will learn about the initiative's scientific progress, such as the development and validation of biomarkers and outcome measures, and the co-design of digital tools with individuals with lived experience.

Sponsored by